FDA Grants Regulatory Approval to Expand Use of Cryoablation to Treat Kidney Cancer
Posted: Monday, January 6, 2020
On December 22, Israel’s IceCure Medical said it received U.S. Food and Drug Administration (FDA) regulatory approval to expand the use of its cryoablation technology to treat benign and cancerous kidney and liver tumors. This treatment uses special needles to inject liquid nitrogen to freeze and destroy tumors without the need for surgery. Until now, cryoablation technology had focused on the treatment of breast tumors.
The FDA also approved the company’s new MultySense system, which has three probes; its earlier system had one needle. With this new system, the company expects to be able to treat larger tumors or a few different tumors at the same time of treatment. The new system is expected to be launched at the end of 2021.